Richard Carroll, PhD, joined Northeast Ohio Medical University, Department of Pharmaceutical Sciences in October 2007. He received his PhD in chemistry from the University of Toledo in Ohio. In 1991, he joined the Neuroscience Therapeutics Department at Parke-Davis in Ann Arbor, Michigan. During his tenure at Parke-Davis, Dr. Carroll was involved in the discovery of novel compounds aimed at treating neurodegenerative diseases. After Parke-Davis merged with Pfizer in 1999, Dr. Carroll became part of the CNS Pharmacology Department at Pfizer. While there he performed significant roles in drug discovery research. Dr. Carroll continues to pursue novel treatments for neurodegenerative diseases. His research focuses on reducing reactive oxygen species in Parkinson’s disease by altering the bioenergetics of neurons through the protein mitoNEET. He has been involved in the synthesis of novel mitoNEET ligands that have been found to be neuroprotective in cellular and pre-clinical models of Parkinson’s disease.